HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in a variety of tumour cells through activation of TRAIL-R1 and TRAIL-R2 death signalling receptors. Here, we describe the characterisation and activity of HGS-ETR1, the first fully human, agonistic TRAIL-R1 mAb that is being developed as an antitumour therapeutic agent. HGS-ETR1 showed specific binding to TRAIL-R1 receptor. HGS-ETR1 reduced the viability of multiple types of tumour cells in vitro, and induced activation of caspase 8, Bid, caspase 9, caspase 3, and cleavage of PARP, indicating activation of TRAIL-R1 alone was sufficient to induce both extrinsic and intrinsic apoptotic pathways. Treatment of cell lines in vitro with HGS-ETR1 enhanced the cytotoxicity of chemotherapeutic agents (camptothecin, cisplatin, carboplatin, or 5-fluorouracil) even in tumour cell lines that were not sensitive to HGS-ETR1 alone. In vivo administration of HGS-ETR1 resulted in rapid tumour regression or repression of tumour growth in pre-established colon, non-small-cell lung, and renal tumours in xenograft models. Combination of HGS-ETR1 with chemotherapeutic agents (topotecan, 5-fluorouracil, and irinotecan) in three independent colon cancer xenograft models resulted in an enhanced antitumour efficacy compared to either agent alone. Pharmacokinetic studies in the mouse following intravenous injection showed that HGS-ETR1 serum concentrations were biphasic with a terminal half-life of 6.9-8.7 days and a steady-state volume of distribution of approximately 60 ml kg(-1). Clearance was 3.6-5.7 ml(-1) day(-1) kg(-1). These data suggest that HGS-ETR1 is a specific and potent antitumour agent with favourable pharmacokinetic characteristics and the potential to provide therapeutic benefit for a broad range of human malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, death receptor-targeted therapies (e.g., DR4/DR5 agonist antibodies) were shown to enhance the antitumor activity of chemotherapy drugs (5-FU, irinotecan) in CRC xenograft models [145,146,147].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries
Jostock, T., Vanhove, M., Brepoels, E., van Gool, R., Daukandt, M., Wehnert, A., van Hegelsom, R., Dransfield, D., Sexton, D., Devlin, M., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.03.014 · Cited by 2,584
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., & Winter, G. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90498-u · Cited by 1,603
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., & Johnson, K. S. (1996) · Nature Biotechnology · doi:10.1038/nbt0396-309 · Cited by 1,027
Self-citationApo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H., & Walczak, H. (2000) · Immunity · doi:10.1016/s1074-7613(00)80211-3 · Cited by 794
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Cited by
Items 101–200 of 305
Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis
Saulle, E., Petronelli, A., Pasquini, L., Petrucci, E., Mariani, G., Biffoni, M., Ferretti, G., Scambia, G., Panici, P. B., Cognetti, F., et al. (2007) · APOPTOSIS · doi:10.1007/s10495-006-0025-9 · Cited by 54
Self-citationMalin, D., Chen, F., Schiller, C. L., Koblinski, J. E., & Cryns, V. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0099 · Cited by 50
Mendoza, F. J., Ishdorj, G., Hu, X., & Gibson, S. B. (2008) · APOPTOSIS · doi:10.1007/s10495-008-0210-0 · Cited by 47
Combined modality therapy with TRAIL or agonistic death receptor antibodies
Amm, H. M., Oliver, P. G., Lee, C. H., Li, Y., & Buchsbaum, D. J. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.5.14671 · Cited by 50
Antibody Phage Display Libraries: Contributions to Oncology
Dantas-Barbosa, C., Brígido, M. M., & Maranhão, A. Q. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13055420 · Cited by 56
“Mapatumumab has agonist activity and demonstrates tumor cell killing by apoptosis in vitro in a broad array of human cancer types and in preclinical animal models [99,100].”
BackgroundYoshida, T., Horinaka, M., Takara, M., Tsuchihashi, M., Mukai, N., Wakada, M., & Sakai, T. (2008) · Environmental Health and Preventive Medicine · doi:10.1007/s12199-008-0041-1 · Cited by 48
“Not only recombinant human TRAIL but also agonistic antibodies for TRAIL receptors have been developed as anti-cancer agents [19, 20].”
BackgroundPetrucci, E., Pasquini, L., Bernabei, M., Saulle, E., Biffoni, M., Accarpio, F., Sibio, S., Giorgio, A. D., Donato, V. D., Casorelli, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035073 · Cited by 48
Razeghian, E., Suksatan, W., Rahman, H. S., Bokov, D. O., Abdelbasset, W. K., Hassanzadeh, A., Marofi, F., Yazdanifar, M., & Jarahian, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.699746 · Cited by 46
“As well, combined treatment with HGS-ETR1 and chemotherapeutic agents, topotecan, 5-FU, and irinotecan caused restored anti-tumor function against colon cancer xenograft models (212).”
BackgroundRetractedMeijer, A., Kruyt, F. A. E., van der Zee, A. G. J., Hollema, H., Le, P., ten Hoor, K. A., Groothuis, G. M. M., Quax, W. J., de Vries, E. G. E., & de Jong, S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.636 · Cited by 47
“…agonistic antibodies and rhTRAIL variants have been generated to specifically target one TRAIL death receptor to enhance efficacy (Ichikawa et al, 2001; Kelley et al, 2005; Pukac et al, 2005; van der Sloot et al, 2006; Adams et al, 2008; Li et al, 2008; Tur et al, 2008; Reis et al, 2009, 2010).”
BackgroundWu, X., Jin, X., Zeng, Y., Hamed, A. M. A. E., & Kakehi, Y. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00632.x · Cited by 46
Chamuleau, M. E. D., Ossenkoppele, G. J., van Rhenen, A., van Dreunen, L., Jirka, S. M. G., Zevenbergen, A., Schuurhuis, G. J., & van de Loosdrecht, A. A. (2011) · Leukemia Research · doi:10.1016/j.leukres.2010.12.032 · Cited by 47
Toscano, F., Fajoui, Z. E., Gay, F., Lalaoui, N., Parmentier, B., Chayvialle, J.-A., Scoazec, J., Micheau, O., Abello, J., & Saurin, J. (2008) · Oncogene · doi:10.1038/onc.2008.52 · Cited by 43
“Alternatively, patients exhibiting wild-type p53 tumours could benefit from ongoing phases I-II clinical trials using either agonistic anti-DR4 or anti-DR5 Oncogene antibodies in human colon cancers (Motoki et al., 2005; Pukac et al., 2005; Mita et al., 2006).”
BackgroundYeow, W.-S., Baras, A., Chua, A., Nguyen, D. M., Sehgal, S., Schrump, D. S., & Nguyen, D. M. (2006) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2006.07.025 · Cited by 41
Kandasamy, K., & Kraft, A. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2368 · Cited by 45
“[Mol Cancer Ther 2008;7(5):1091–100] Introduction”
Hyaluronate–Gold Nanorod/DR5 Antibody Complex for Noninvasive Theranosis of Skin Cancer
Lee, H., Lee, J. H., Kim, J., Mun, J., Chung, J., Koo, H., Kim, C., Yun, S. H., & Hahn, S. K. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b11319 · Cited by 41
Journey of TRAIL from bench to bedside and its potential role in immuno-oncology
Naoum, G. E., Buchsbaum, D. J., Tawadros, F., Farooqi, A. A., & Arafat, W. O. (2017) · Oncology Reviews · doi:10.4081/oncol.2017.332 · Cited by 49
Naimi, A., Movassaghpour, A. A., Hagh, M. F., Talebi, M., Entezari, A., Jadidi‐Niaragh, F., & Solali, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.082 · Cited by 45
Shamimi-Noori, S. M., Yeow, W.-S., Ziauddin, M. F., Xin, H., Tran, T.-V., Xie, J., Loehfelm, A., Patel, P. V., Yang, J., Schrump, D. S., et al. (2008) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701120 · Cited by 45
A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells
Petrucci, E., Pasquini, L., Petronelli, A., Saulle, E., Mariani, G., Riccioni, R., Biffoni, M., Ferretti, G., Benedetti-Panici, P., Cognetti, F., et al. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.01.011 · Cited by 40
Self-citationDeRosier, L. C., Buchsbaum, D. J., Oliver, P. G., Huang, Z., Sellers, J. C., Grizzle, W. E., Wang, W., Zhou, T., Zinn, K. R., Long, J. W., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1075 · Cited by 43
A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells
Kobayashi, E., Kishi, H., Ozawa, T., Hamana, H., Nakagawa, H., Jin, A., Lin, Z., & Muraguchi, A. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.10.024 · Cited by 39
Ohtsuki, T., Tamaki, M., Toume, K., & Ishibashi, M. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.11.022 · Cited by 39
Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin
Tsai, W. S., Yeow, W.-S., Chua, A., Reddy, R. M., Nguyen, D. M., Schrump, D. S., & Nguyen, D. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0514 · Cited by 42
“(4), or recombinant human agonistic anti-DR4 or anti-DR5 monoclonal antibodies (32) are commonly used to activate TRAIL receptor for the induction of apoptosis of cancer cells.”
BackgroundTan, T.-T., & White, E. P. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_5 · Cited by 43
Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development
Lee‐Sherick, A. B., Linger, R. M. A., Gore, L., Keating, A. K., & Graham, D. K. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08282.x · Cited by 42
“The TRAIL mAb has been found to have a longer half-life compared to native or recombinant TRAIL (Ashkenazi et al, 1999; Pukac et al, 2005).”
BackgroundA cell-based high-throughput screen to identify synergistic TRAIL sensitizers
Booth, N. L., Sayers, T. J., Brooks, A. D., Thomas, C. L., Jacobsen, K. M., Goncharova, E. I., McMahon, J. B., & Henrich, C. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0637-8 · Cited by 38
“ETR1, mapatumumab) or TR2 (HGS-ETR2, HGS-TR2 J, lexatumumab) specificity [15, 30, 49, 67, 73].”
Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma
McCarthy, M. M., DiVito, K. A., Sznol, M., Kovacs, D., Halaban, R., Berger, A. J., Flaherty, K. T., Camp, R. L., Lazova, R. Z., Rimm, D. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0190 · Cited by 38
Vigneswaran, N., Baucum, D. C., Wu, J. G., Lou, Y., Bouquot, J. E., Müller, S., & Zacharias, W. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-108 · Cited by 43
Gong, J., Yang, D. J., Kohanim, S., Humphreys, R. C., Broemeling, L. D., & Kurzrock, R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0188 · Cited by 37
Self-citationSun, D., Chang, Y.-C., Lien, T.-S., King, C., Shih, Y., Huang, H.-S., Wang, T.-Y., Li, C.-R., Lee, C.-C., Hsu, P., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500136 · Cited by 36
“crosslinking of DRs by Abs can lead to cell death (19, 20), this prompts the existence of a DR crossreactive fraction.”
BackgroundKundu, M., Greer, Y. E., Dine, J. L., & Lipkowitz, S. (2022) · Cells · doi:10.3390/cells11233717 · Cited by 41
Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism
Dobson, C., Main, S. H., Newton, P., Chodorge, M., Cadwallader, K. A., Humphreys, R. C., Albert, V. R., Vaughan, T. J., Minter, R., & Edwards, B. M. (2009) · mAbs · doi:10.4161/mabs.1.6.10057 · Cited by 37
Self-citationImpact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma
Röder, C., Trauzold, A., & Kalthoff, H. (2010) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2010.10.008 · Cited by 47
High-efficiency antibody discovery achieved with multiplexed microscopy
Izquierdo, S. M., Varela, S., Park, M., Collarini, E. J., Lu, D., Pramanick, S., Rucker, J. B., Lopalco, L., Etches, R., & Harriman, W. D. (2016) · Microscopy · doi:10.1093/jmicro/dfw014 · Cited by 37
“Binding of the ligand TRAIL can induce apoptosis in a variety of cell types and agonistic antibodies to these receptors are also pro-apoptotic [43–45].”
BackgroundCooper, W. A., Kohonen‐Corish, M. R. J., Zhuang, L., McCaughan, B. C., Kennedy, C. W., Screaton, G. R., Sutherland, R. L., & Lee, C. S. (2008) · Cancer · doi:10.1002/cncr.23528 · Cited by 35
Oliver, P. G., LoBuglio, A. F., Zinn, K. R., Kim, H., Li, N., Zhou, T., Wang, W., & Buchsbaum, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1392 · Cited by 35
Salinomycin Potentiates the Cytotoxic Effects of TRAIL on Glioblastoma Cell Lines
Calzolari, A., Saulle, E., Angelis, M. L. D., Pasquini, L., Boe, A., Pelacchi, F., Ricci‐Vitiani, L., Baiocchi, M., & Testa, U. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094438 · Cited by 37
Cheng, H., Hong, B., Zhou, L., Allen, J. E., Tai, G., Humphreys, R. C., Dicker, D. T., Liu, Y. Y., & El‐Deiry, W. S. (2012) · Cell Cycle · doi:10.4161/cc.21670 · Cited by 34
“However, the half-life of mapatumumab is ~9 days compared with less than 30 min for TRAIL in vivo.(23,24) The stability of mapatumumab and lexatumumab makes them attractive agents for use in humans.”
BackgroundSelf-citationLi, J., Anderson, M. G., Tucker, L. A., Shen, Y., Glaser, K. B., & Shah, O. J. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.174 · Cited by 37
Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5
van Geelen, C. M. M., Pennarun, B., Le, P. T., de Vries, E. G. E., & de Jong, S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-39 · Cited by 34
“In contrast, agonistic DR4 or DR5 antibodies have been suggested to trigger the formation of multimeric complexes consisting of only one specific receptor, which consequently enables them to bypass the decoy receptors [21,22].”
BackgroundPrognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas
Granci, V., Bibeau, F., Kramar, A., Boissière‐Michot, F., Thézenas, S., Thirion, A., Gongora, C., Martineau, P., Rio, M. D., & Ychou, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.042 · Cited by 35
Sung, E.-S., Kim, A., Park, J. S., Chung, J., Kwon, M.-H., & Kim, Y. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0521-9 · Cited by 33
“Thus the cell-surface expression levels of DR4 and DR5 in leukemia cells are not strictly correlated with susceptibility to AY4and TRAIL-induced cell death, in agreement with previous reports [11, 28, 36].”
Li, X., Lu, W., Liang, G., Ruan, G. R., Hong, H., Long, C., Zhang, Y., Liu, Y., Wang, J., Zhang, X., et al. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01643.x · Cited by 32
Congy‐Jolivet, N., Probst, A., Watier, H., & Thibault, G. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.06.013 · Cited by 37
Xiaowen, H., & Sun, Y. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-1737-2 · Cited by 32
Song, X., Kim, S.-Y., & Lee, Y. J. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0209-t · Cited by 34
“Our data and literatures (19) show that oxaliplatin/TRAIL treatment elevates the intracellular level of ROS.”
InfluentialReddy, R. M., Yeow, W.-S., Chua, A., Nguyen, D. M., Baras, A., Ziauddin, M. F., Shamimi-Noori, S. M., Maxhimer, J. B., Schrump, D. S., & Nguyen, D. M. (2006) · APOPTOSIS · doi:10.1007/s10495-006-0484-z · Cited by 34
“This is due to the unacceptable hepatotoxicity incurred by cross-linked soluble FasL or antiFas antibodies [3, 4] which is not seen with Apo2L/TRAIL [1, 5, 6] or agonistic TRAIL-R1 monoclonal antibody [2].”
Schneider, H., Yanakieva, D., Palacios, A. M., Deweid, L., Becker, B., Englert, S., Avrutina, O., & Kolmar, H. (2019) · ChemBioChem · doi:10.1002/cbic.201900251 · Cited by 30
Chodorge, M., Fourage, L., Ravot, G., Jermutus, L., & Minter, R. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn013 · Cited by 30
Song, K., Benhaga, N., Anderson, R. L., & Khosravi‐Far, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3501 · Cited by 30
“Recently, human agonist antibodies to TRAIL receptors 1 and 2 have been tested for their antitumor efficacy, have shown promising results in xenograft models (11, 12), and have been currently used in clinical trials.”
BackgroundNguyen, D. M., Yeow, W.-S., Ziauddin, M. F., Baras, A., Tsai, W. S., Reddy, R. M., Chua, A., Cole, G. W., & Schrump, D. S. (2006) · The Cancer Journal · doi:10.1097/00130404-200607000-00004 · Cited by 32
Emerging Monoclonal Antibodies and Related Agents for the Treatment of Chronic Lymphocytic Leukemia
Robak, T. (2012) · Future Oncology · doi:10.2217/fon.12.157 · Cited by 30
Wu, X., & Kakehi, Y. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2667 · Cited by 29
High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide
Petronelli, A., Saulle, E., Pasquini, L., Petrucci, E., Mariani, G., Biffoni, M., Ferretti, G., Scambia, G., Panici, P. B., Greggi, S., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.03.018 · Cited by 30
Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes
Allen, J. E., Ferrini, R., Dicker, D. T., Batzer, G. M., Chen, E., Oltean, D. I., Lin, B., Renshaw, M. W., Kretz-Rommel, A., & El‐Deiry, W. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0366 · Cited by 28
“These improvements brought the efficacy of the DR4 AtrimerTM complexes into a range comparable to, or better than, recombinant TRAIL as well as such reported values for mapatumumab (15-16) (Table 1).”
ResultFiveash, J. B., Gillespie, G. Y., Oliver, P. G., Zhou, T., Belenky, M. L., & Buchsbaum, D. J. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.02.005 · Cited by 28
The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases
Shepard, B. D., & Badley, A. D. (2009) · Anti-Infective Agents · doi:10.2174/187152109787846060 · Cited by 32
“While several agonistic anti-TRAIL-R antibodies have been developed, a few fully humanized monoclonal antibodies emerged from preclinical studies after demonstration that each induced apoptotic death in a wide variety of cancer cell lines in vitro and in xenograft mouse models [161-163].”
BackgroundTherapeutics Targeting the Core Apoptotic Machinery
Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A. (2021) · Cancers · doi:10.3390/cancers13112618 · Cited by 26
“In KRAS mutant cancers, endogenous TRAIL and its receptors have been highlighted to promote tumor growth and metastases by activating Rac1 and promoting migration and invasion of cancer cells, with a direct correlation seen between the level of expression of TRAIL‐R2 and the extent of metastasis seen in patients [82,8…”
BackgroundMethodHarrington, C. T., Sotillo, E., Robert, A., Hayer, K. E., Bogusz, A. M., Psathas, J. N., Yu, D., Taylor, D. M., Dang, C. V., Klein, P. S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0454-4 · Cited by 28
Phosphorothioate-Modified TLR9 Ligands Protect Cancer Cells against TRAIL-Induced Apoptosis
Chiron, D., Pellat‐Deceunynck, C., Maillasson, M., Bataille, R., & Jégo, G. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901436 · Cited by 31
“To better characterize the mechanism of apoptosis inhibition observed with CpG ODN, we replaced human recombinant TRAIL with mapatumumab and lexatumumab, two agonist Abs directed against DR4 or DR5, respectively (26, 27).”
MethodMurai, M., Inoué, T., Suzuki‐Karasaki, M., Ochiai, T., Ra, C., NISHIDA, S., & Suzuki‐Karasaki, Y. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1656 · Cited by 26
Sung, E.-S., Park, K.-J., Lee, S., Jang, Y.-S., Park, S.-K., Park, Y.-H., Kwag, W.-J., Kwon, M., & Kim, Y. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0235 · Cited by 28
“In contrast to previously reported anti-DR4 agonistic mAbs, 4H6 (7), 2E12 (8), and DR4-A (34), which required cross-linking agent to trigger potent apoptosis, the bivalent anti-DR4 AY4 alone was enough to activate DR4 to transduce cell death signaling for the TRAIL-sensitive cells, like anti-DR4 HGS-ETR1 mAb (9, 11).”
BackgroundInfluentialHighlights in experimental therapeutics
Burger, A. M. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.03.012 · Cited by 28
Naturally occurring, tumor-specific, therapeutic proteins
Argiris, K., Panethymitaki, C., & Tavassoli, M. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011004 · Cited by 31
Novel antibodies against follicular non-Hodgkin’s lymphoma
van Meerten, T., & Hagenbeek, A. (2011) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2011.03.002 · Cited by 25
Emerging New Agents for the Management of Patients with Non-Small Cell Lung Cancer
Capelletto, E., & Novello, S. (2012) · Drugs · doi:10.2165/1163028-s0-000000000-00000 · Cited by 25
Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma
Younes, M., Georgakis, G. V., Rahmani, M., Beer, D. G., & Younes, A. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.013 · Cited by 26
Bavi, P. P., Prabhakaran, S., Abubaker, J. A., Qadri, Z., George, T., Al-Sanea, N. A., Abduljabbar, A. S., Ashari, L. H. S., Alhomoud, S. J., Al‐Dayel, F., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-203 · Cited by 32
“The TRAIL receptors, TRAIL-R1 and TRAIL-R2, are highly expressed in many cancer cells including CRC [8-10].”
BackgroundTargeting regulated cell death pathways in cancers for effective treatment: a comprehensive review
Saxena, R., Welsh, C. M., & He, Y.-W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1462339 · Cited by 34
TRAIL-Based Therapy in Pediatric Bone Tumors: How to Overcome Resistance
Guiho, R., Biteau, K., Heymann, D., & Rédiní, F. (2015) · Future Oncology · doi:10.2217/fon.14.293 · Cited by 24
Nagane, M., Shimizu, S., Mori, E., Kataoka, S., & Shiokawa, Y. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop069 · Cited by 28
Pharmacodynamics of current and emerging treatments for cervical cancer
Dueñas‐González, A., & González‐Fierro, A. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1648431 · Cited by 26
“Moreover, this agent synergizes in vitro and in vivo with chemotherapy and has a favorable pharmacokinetic profile [89,90].”
BackgroundMoretto, P., & Hotte, S. J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902752463 · Cited by 22
“Treatment with various concentrations of mapatumumab resulted in a dose-dependent reduction of cell viability that was associated with activation of caspase-3 and/or -7 in most cell lines [49] .”
BackgroundInfluentialExosomal delivery of TRAIL and miR‑335 for the treatment of hepatocellular carcinoma (Review)
Thapa, N., Chwae, Y., Yoo, K. H., Won, T., Kang, D., Choi, D. A., & Kim, J. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5206 · Cited by 23
“Similarly, in preclinical tumor xenograft mouse models, mapatumumab and lexatumumab have failed to eradi‐ cate tumors (74,75).”
BackgroundNovel Therapies Targeting the Apoptosis Pathway for the Treatment of Acute Myeloid Leukemia
Schimmer, A. D. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0037-x · Cited by 24
Jin, X., Wu, X., Nouh, M. A. A., & Kakehi, Y. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.01.018 · Cited by 21
The Potential of Death Receptor 4– and 5–Directed Therapies in the Treatment of Lung Cancer
Camidge, D. R. (2007) · Clinical Lung Cancer · doi:10.3816/clc.2007.n.024 · Cited by 21
Wang, H., Yang, T., & Wu, X. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.06.003 · Cited by 20
“…lines in vitro and in animal models (Galligan et al., 2005; Ganten et al., 2004; Haag et al., 2011; Keane et al., 1999; Lacour et al., 2003; Meurette et al., 2005; Mizutani et al., 2002; Pukac et al., 2005; Shimoyama et al., 2002; Stagni et al., 2010; von Haefen et al., 2004; Zhu et al., 2013).”
BackgroundTRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cellsin vitroandin vivo
Piao, X., Ozawa, T., Hamana, H., Shitaoka, K., Jin, A., Kishi, H., & Muraguchi, A. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1131380 · Cited by 21
“that of HGS-ETR1, an agonistic anti-TR1 antibody used in clinical trials.(22) Therefore, TR1-IgM(J+) 422 could be an efficient”
BackgroundMethodTsai, C.-L., Sun, D., Su, M.-T., Lien, T.-S., Chen, Y., Lin, C.-Y., Huang, C., King, C., Li, C.-R., Chen, T.-H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-62958-0 · Cited by 20
Duiker, E. W., Dijkers, E. C. F., Heerspink, H. J. L., de Jong, S., van der Zee, A., Jager, P. L., Kosterink, J. G. W., de Vries, E., & Hooge, M. N. L. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01718.x · Cited by 20
“Both rhTRAIL and mapatumumab have shown in vitro and in vivo efficacy in a wide variety of human tumour cell lines and xenograft models (LeBlanc and Ashkenazi, 2003; Pukac et al., 2005; Marini et al., 2006).”
BackgroundFn14·TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog
Prigozhina, T. B., Szafer, F., Aronin, A., Tzdaka, K., Amsili, S., Makdasi, E., Shani, N., & Elhalel, M. D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.026 · Cited by 20
AXL Mediates TRAIL Resistance in Esophageal Adenocarcinoma
Hong, J., & Belkhiri, A. (2013) · Neoplasia · doi:10.1593/neo.122044 · Cited by 18
“Recombinant proteins, such as TRAIL, or agonistic human monoclonal antibodies against DR4 or DR5 death receptors are frequently used to induce apoptosis of cancer cells [12,13].”
BackgroundSmall molecule inhibitor of apoptosis proteins antagonists: a patent review
Hird, A. W., Aquila, B. M., Hennessy, E. J., Vasbinder, M. M., & Yang, B. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1041922 · Cited by 21
“Compound 10 (1) from Aegera Therapeutics’s 2011 PCT filing [35] was found to be active in a metastatic breast cancer xenograft model, particularly in combination with a TNFrelated apoptosis-inducing ligand (TRAIL) antibody [36].”
BackgroundThe role of the mitochondria in mediating cytotoxicity of anti-cancer therapies
Nguyen, D. M., & Hussain, M. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-006-9055-9 · Cited by 23
Mechanisms of TRAIL-induced apoptosis in leukemic plasmacytoid dendritic cells
Blum, A., Chaperot, L., Molens, J., Foissaud, V., Plantaz, D., & Plumas, J. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.08.002 · Cited by 27
Fryer, T., Rogers, J. D., Mellor, C., Kohler, T. N., Minter, R., & Hollfelder, F. (2022) · ACS Central Science · doi:10.1021/acscentsci.2c00576 · Cited by 17
Cell survival and apoptosis‐related molecules in cancer cells in effusions: A comprehensive review
Kleinberg, L., & Davidson, B. (2009) · Diagnostic Cytopathology · doi:10.1002/dc.21095 · Cited by 20
Song, X., Kim, H., Kim, S., Basse, P. H., Park, B.-H., Lee, B., & Lee, Y. J. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24023 · Cited by 18
“Like the native ligand TRAIL, Mapa mediates apoptosis by binding to TRAILR1, leading to activation of the caspase cascade and subsequent cell death [Pukac et al., 2005].”
BackgroundShimada, O., Wu, X., Jin, X., Nouh, M. A. A., Fiscella, M., Albert, V. R., Matsuda, T., & Kakehi, Y. (2007) · Urology · doi:10.1016/j.urology.2006.12.007 · Cited by 18
Self-citationHarrington, C. T., Sotillo, E., Robert, A., Hayer, K. E., Bogusz, A. M., Psathas, J. N., Yu, D., Taylor, D. M., Dang, C. V., Klein, P. S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0650-2 · Cited by 19
Stolfi, C., Caruso, R., Franzè, E., Rizzo, A., Rotondi, A., Monteleone, I., Fantini, M. C., Pallone, F., & Monteleone, G. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0316 · Cited by 17
“Mol Cancer Ther; 10(10) October 2011 Molecular Cancer Therapeutics 1978”
BackgroundInfluentialCytotoxic IgG: Mechanisms, functions, and applications
Wöhner, M., & Nimmerjahn, F. (2025) · Immunity · doi:10.1016/j.immuni.2025.05.008 · Cited by 22
Xie, X. (1994) · Oncology Reports · doi:10.3892/or_00000245 · Cited by 16
“The initial optimism for TRAIL was tempered somehow because studies with early recombinant forms of TRAIL also induced apoptosis in normal this observed toxicity (15,16).”
Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers
Hochnadel, I., Kossatz-Boehlert, U., Jedicke, N., Lenzen, H., Manns, M. P., & Yevsa, T. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1359362 · Cited by 20
“Agonistic antibodies have been shown to promote tumor regression in mouse models of other tumor entities.(100) Results of the clinical approach have also not been published.”
BackgroundTargeting NF-κB in Anticancer Adjunctive Chemotherapy
Haefner, B. (2006) · Cancer treatment and research · doi:10.1007/0-387-26283-0_10 · Cited by 18
Yoshida, T., Horinaka, M., & Sakai, T. (2010) · Environmental Health and Preventive Medicine · doi:10.1007/s12199-009-0128-3 · Cited by 16
“Recombinant TRAIL and agonistic antibodies against DR5 and DR4 are currently being tested in clinical studies as treatments against malignant tumors, but some types of malignant tumor cells remain tolerant to TRAIL [16–18].”
BackgroundDeRosier, L. C., Huang, Z., Sellers, J. C., Buchsbaum, D. J., & Vickers, S. M. (2006) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2006.08.007 · Cited by 16
“Although newer zinc-optimized recombinant forms of TRAIL have avoided this hepatotoxicity,(13,24) researchers worked to develop agonistic monoclonal antibodies to specific death receptors in an effort to circumvent this observed toxicity.(25,26) Ichikawa et al.”
BackgroundResultSensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis by hyperthermia
Moulin, M., Dumontet, C., & Arrigo, A. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.10.019 · Cited by 15
Initial testing (stage 1) of mapatumumab (HGS‐ETR1) by the pediatric preclinical testing program
Smith, M. A., Morton, C. L., Kolb, E. A., Gorlick, R. G., Keir, S. T., Carol, H., Lock, R. B., Kang, M. H., Reynolds, C. P., Maris, J. M., et al. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22188 · Cited by 16
“The limited activity of mapatumumab against the PPTP in vivo models is unlikely to be due to failure to achieve effective systemic exposures, as mapatumumab at the dose and schedule used by the PPTP showed substantial preclinical activity against selected adult cancer models [1].”
BackgroundMethod
Metadata
- Authors
- Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., Carrell, J., Boyd, E., Yao, X. T., Zhang, L., Zhong, L., von Kerczek, A., Shepard, L., Vaughan, T., Edwards, B., Dobson, C., Salcedo, T., & Albert, V
- Affiliations
- Human Genome Sciences (United States) (US)
- Recombinant Antibody Technology (United Kingdom) (GB)
- Corresponding author
- Pukac, L
- Venue
- British Journal of Cancer
- Published
- 2005-04
- Volume
- 92
- Issue
- 8
- Pages
- 1430-1441
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2361994
- OpenAlex
- W1974144614
- Cited by
- 306
- References
- 56
- Citations by year
- 2025: 6 · 2024: 6 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 11 · 2018: 3 · 2017: 8 · 2016: 8 · 2015: 12 · 2014: 7 · 2013: 13 · 2012: 16
- FWCI
- 14.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- TRAIL-R1, TRAIL receptor 1, agonistic monoclonal antibody, TRAIL, apoptosis, caspase activation, PARP cleavage, combination chemotherapy, colon cancer, non-small cell lung cancer, renal tumours, xenograft models, pharmacokinetics, cancer therapy
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody Specificity, Antineoplastic Agents, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Half-Life, Humans, Male, Mice, Nude, Neoplasms, Experimental, Blotting, Western, Apoptosis, Receptors, Tumor Necrosis Factor, Cell Line, Tumor, Mice, Receptors, TNF-Related Apoptosis-Inducing Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.